Search
Cisplatin Treatment Options in Canada
A collection of 326 research studies where Cisplatin is the interventional treatment. These studies are located in the Canada . Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
49 - 60 of 326
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Recruiting
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: Research Site, Phoenix, Arizona +180 locations
Research Site, Phoenix, Arizona
Research Site, Duarte, California
Research Site, Santa Rosa, California
Research Site, Aurora, Colorado
Research Site, Jacksonville, Florida
Research Site, Atlanta, Georgia
Research Site, Chicago, Illinois
Research Site, Baltimore, Maryland
Research Site, Rochester, Minnesota
Research Site, Saint Louis, Missouri
Research Site, East Brunswick, New Jersey
Research Site, Commack, New York
Research Site, Valhalla, New York
Research Site, Cleveland, Ohio
Research Site, Cleveland, Ohio
Research Site, Cleveland, Ohio
Research Site, Columbus, Ohio
Research Site, Independence, Ohio
Research Site, Portland, Oregon
Research Site, Portland, Oregon
Research Site, Portland, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Houston, Texas
Research Site, Fairfax, Virginia
Research Site, Chermside, Not set
Research Site, Clayton, Not set
Research Site, Melbourne, Not set
Research Site, Nedlands, Not set
Research Site, Westmead, Not set
Research Site, Anderlecht, Not set
Research Site, Antwerpen, Not set
Research Site, Gent, Not set
Research Site, Hasselt, Not set
Research Site, Leuven, Not set
Research Site, Sint-Niklaas, Not set
Research Site, Barretos, Not set
Research Site, Fortaleza, Not set
Research Site, Joao Pessoa, Not set
Research Site, Porto Alegre, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Santo Andre, Not set
Research Site, São Paulo, Not set
Research Site, Edmonton, Alberta
Research Site, Hamilton, Ontario
Research Site, London, Ontario
Research Site, Ottawa, Ontario
Research Site, Toronto, Ontario
Research Site, Montreal, Quebec
Research Site, Quebec, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Harbin, Not set
Research Site, Kunming, Not set
Research Site, Lanzhou, Not set
Research Site, Nanchang, Not set
Research Site, Ningbo, Not set
Research Site, Qingdao, Not set
Research Site, Shandong, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Taiyuan, Not set
Research Site, Taiyuan, Not set
Research Site, Tianjin, Not set
Research Site, Tianjin, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Zhengzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Aarhus N, Not set
Research Site, Copenhagen, Not set
Research Site, Brest, Not set
Research Site, Creteil Cedex, Not set
Research Site, Le Mans Cedex, Not set
Research Site, Lille, Not set
Research Site, Lyon, Not set
Research Site, Marseille Cedex 20, Not set
Research Site, Montpellier, Not set
Research Site, Paris, Not set
Research Site, Rouen, Not set
Research Site, Saint Herblain, Not set
Research Site, Strasbourg, Not set
Research Site, Toulouse, Not set
Research Site, Berlin, Not set
Research Site, Berlin, Not set
Research Site, Bochum, Not set
Research Site, Essen, Not set
Research Site, Essen, Not set
Research Site, Gauting, Not set
Research Site, Georgsmarienhuette, Not set
Research Site, Grosshansdorf, Not set
Research Site, Hamburg, Not set
Research Site, Heidelberg, Not set
Research Site, Kiel, Not set
Research Site, Köln, Not set
Research Site, Muenster, Not set
Research Site, Regensburg, Not set
Research Site, Alessandria, Not set
Research Site, Bari, Not set
Research Site, Bergamo, Not set
Research Site, Milan, Not set
Research Site, Monza, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Parma, Not set
Research Site, Rozzano, Not set
Research Site, Varese, Not set
Research Site, Amagasaki-shi, Not set
Research Site, Hakodate-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Kitaadachi-gun, Not set
Research Site, Kitakyushu-shi, Not set
Research Site, Matsuyama-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nishinomiya-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Tokyo, Not set
Research Site, Ube-shi, Not set
Research Site, Cheongju-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Ulsan, Not set
Research Site, Amsterdam, Not set
Research Site, Eindhoven, Not set
Research Site, Rotterdam, Not set
Research Site, Lørenskog, Not set
Research Site, Oslo, Not set
Research Site, Bydgoszcz, Not set
Research Site, Bystra, Not set
Research Site, Olsztyn, Not set
Research Site, Poznań, Not set
Research Site, Rzeszów, Not set
Research Site, Warszawa, Not set
Research Site, Amanzimtoti, Not set
Research Site, Cape Town, Not set
Research Site, Johannesburg, Not set
Research Site, Johannesburg, Not set
Research Site, Kimberly, Not set
Research Site, Polokwane, Not set
Research Site, Pretoria, Not set
Research Site, Pretoria, Not set
Research Site, Barakaldo, Not set
Research Site, Barcelona, Not set
Research Site, Madrid, Not set
Research Site, Oviedo, Not set
Research Site, Baden, Not set
Research Site, Basel, Not set
Research Site, Bern, Not set
Research Site, Fribourg, Not set
Research Site, St. Gallen, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Adana, Not set
Research Site, Ankara, Not set
Research Site, Ankara, Not set
Research Site, Diyarbakir, Not set
Research Site, Izmir, Not set
Research Site, Cambridge, Not set
Research Site, Cardiff, Wales, Not set
Research Site, Leeds, Not set
Research Site, Leicester, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Middlesborough, Not set
Research Site, Newcastle-upon-Tyne, Not set
Research Site, Portsmouth, Not set
Research Site, Taunton, Not set
Conditions: Unresectable Pleural Mesothelioma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Active Not Recruiting
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed b... Read More
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: Infirmary Cancer Care ( Site 0022), Mobile, Alabama +139 locations
Infirmary Cancer Care ( Site 0022), Mobile, Alabama
Los Angeles Hematology Oncology Medical Group ( Site 0006), Los Angeles, California
VA West Los Angeles Medical Center ( Site 0004), Los Angeles, California
Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014), Boca Raton, Florida
Fort Wayne Medical Oncology and Hematology ( Site 0013), Fort Wayne, Indiana
Dana-Farber Cancer Institute ( Site 0018), Boston, Massachusetts
Cancer and Hematology Centers of Western Michigan ( Site 0001), Grand Rapids, Michigan
Hattiesburg Clinic Hematology/Oncology ( Site 0003), Hattiesburg, Mississippi
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005), Lancaster, Pennsylvania
Blue Ridge Cancer Care ( Site 0015), Blacksburg, Virginia
University of Virginia Cancer Center ( Site 0019), Charlottesville, Virginia
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203), Ciudad Autonoma de Buenos Aires, Buenos Aires
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0200), Buenos Aires, Caba
Hospital Provincial del Centenario ( Site 0205), Rosario, Santa Fe
Sanatorio Parque ( Site 0202), Rosario, Santa Fe
Nepean Hospital ( Site 2700), Kingswood, New South Wales
Calvary Mater Newcastle ( Site 2703), Waratah, New South Wales
Frankston Hospital-Oncology and Haematology ( Site 2702), Frankston, Victoria
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701), Melbourne, Victoria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0505), Linz, Oberosterreich
Kepler Universitätsklinikum ( Site 0507), Linz, Oberosterreich
Medizinische Universität Graz ( Site 0504), Graz, Steiermark
Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0502), Wien, Not set
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0501), Wien, Not set
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0106), Kingston, Ontario
Lakeridge Health ( Site 0102), Oshawa, Ontario
Anhui Cancer Hospital ( Site 2915), Hefei, Anhui
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2901), Beijing, Beijing
Beijing Peking Union Medical College Hospital ( Site 2921), Beijing, Beijing
Fujian Provincial Cancer Hospital-oncology department ( Site 2904), Fuzhou, Fujian
Harbin Medical University Cancer Hospital-oncology of department ( Site 2920), Harbin, Heilongjiang
Henan Cancer Hospital ( Site 2916), Zhengzhou, Henan
Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2912), Wuhan, Hubei
Hubei Cancer Hospital ( Site 2922), Wuhan, Hubei
Hunan Cancer Hospital ( Site 2907), Changsha, Hunan
The First Affiliated Hospital of Soochow University ( Site 2913), Suzhou, Jiangsu
Jilin Cancer Hospital-GCP office ( Site 2909), Changchun, Jilin
The First Hospital of Jilin University ( Site 2914), Changchun, Jilin
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2910), Xi'an, Shaanxi
Shanghai Chest Hospital-Oncology department ( Site 2900), Shanghai, Shanghai
Fudan University Shanghai Cancer Center ( Site 2908), Shanghai, Shanghai
Sichuan Cancer hospital. ( Site 2923), Chengdu, Sichuan
West China Hospital Sichuan University ( Site 2903), Chengdu, Sichuan
Sir Run Run Shaw Hospital-Medical Oncology ( Site 2906), Hangzhou, Zhejiang
Zhejiang Cancer Hospital-Oncology ( Site 2919), Hangzhou, Zhejiang
Vaasan Keskussairaala-Department of Clinical Oncology ( Site 0700), Vaasa, Pohjanmaa
Oulun yliopistollinen sairaala-Oncology and Hematology ( Site 0702), Oulu, Pohjois-Pohjanmaa
Turku University Hospital-The Department of Pulmonary Medicine ( Site 0701), Turku, Varsinais-Suomi
Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0805), Marseille, Bouches-du-Rhone
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 0800), Toulouse, Haute-Garonne
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Unité d'oncologie thoracique et cutané ( Site 0803), Limoges, Haute-Vienne
Thoraxklinik-Heidelberg gGmbH-Studienzentrum Thoraxonkologie ( Site 0905), Heidelberg, Baden-Wurttemberg
Lungenfachklinik Immenhausen-Thoracic Oncology ( Site 0907), Immenhausen, Hessen
Medizinische Hochschule Hannover-Department of Pneumology ( Site 0901), Hannover, Niedersachsen
LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein
SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 0900), Gera, Thuringen
Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 1002), Athens, Attiki
Sotiria Thoracic Diseases Hospital of Athens ( Site 1003), Athens, Attiki
Metropolitan Hospital ( Site 1001), Athens, Attiki
University General Hospital of Heraklion ( Site 1004), Heraklion, Irakleio
European Interbalkan Medical Center ( Site 1000), Thessaloniki, Not set
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1105), Kecskemét, Bacs-Kiskun
Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia (Dr. Szalai Zsuzsanna) ( Site 1102), Gyor, Gyor-Moson-Sopron
Reformatus Pulmonologiai Centrum-Onkopulmonologiai Jarobeteg Centrum ( Site 1101), Torokbalint, Pest
Somogy Megyei Kaposi Mór Oktató Kórház-Pulmonologiai Osztaly ( Site 1104), Kaposvár, Somogy
St. James's Hospital ( Site 1200), Dublin, Not set
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 1201), Dublin, Not set
Rambam Health Care Campus-Oncology ( Site 1301), Haifa, Not set
Shaare Zedek Medical Center-Oncology ( Site 1300), Jerusalem, Not set
Sheba Medical Center-ONCOLOGY ( Site 1302), Ramat Gan, Not set
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1402), Naples, Campania
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401), Milan, Lombardia
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1403), Rozzano, Milano
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1400), Rome, Roma
Aichi Cancer Center ( Site 3016), Nagoya, Aichi
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 3012), Matsuyama, Ehime
Kurume University Hospital ( Site 3014), Kurume, Fukuoka
National Hospital Organization Hokkaido Cancer Center ( Site 3015), Sapporo, Hokkaido
Kanazawa University Hospital ( Site 3006), Kanazawa, Ishikawa
Kanagawa Cancer Center ( Site 3004), Yokohama, Kanagawa
Sendai Kousei Hospital ( Site 3001), Sendai, Miyagi
Niigata Cancer Center Hospital ( Site 3005), Niigata-shi, Niigata
Kansai Medical University Hospital ( Site 3009), Hirakata, Osaka
Shizuoka Cancer Center ( Site 3007), Nagaizumi, Shizuoka
Cancer Institute Hospital of JFCR ( Site 3003), Koto, Tokyo
National Hospital Organization Kyushu Medical Center ( Site 3013), Fukuoka, Not set
Okayama University Hospital ( Site 3011), Okayama, Not set
Chonnam National University Hwasun Hospital-Pulmonology ( Site 2800), Hwasun, Jeonranamdo
Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2801), Deagu, Taegu-Kwangyokshi
Chungnam national university hospital-Department of Internal Medicine ( Site 2802), Daejeon, Taejon-Kwangyokshi
Korea University Guro Hospital-Internal Medicine ( Site 2803), Seoul, Not set
Klaipeda University Hospital-Oncology chemotherapy ( Site 1502), Klaipeda, Klaipedos Miestas
National Cancer Institute-Department of Thoracic Surgery and Oncology ( Site 1501), Vilnius, Vilniaus Miestas
Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 1500), Kaunas, Not set
Arké SMO S.A. de C.V. ( Site 0401), Mexico, Distrito Federal
Hospital Civil Fray Antonio Alcalde-Oncology ( Site 0407), Guadalajara, Jalisco
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 0403), Guadalajara, Jalisco
iCan Oncology Center Centro Medico AVE ( Site 0406), Monterrey, Nuevo Leon
Centro de Investigacion Clinica de Oaxaca ( Site 0410), Oaxaca, Not set
Medische Centrum Leeuwarden ( Site 1619), Leeuwarden, Fryslan
Ziekenhuis Rijnstate ( Site 1606), Arnhem, Gelderland
Maastricht UMC+-Pulmonary disease ( Site 1602), Maastricht, Limburg
Jeroen Bosch Hospital-Pulmonology ( Site 1605), Den Bosch, Noord-Brabant
Isala, locatie Zwolle-Poli Longziekten ( Site 1612), Zwolle, Overijssel
Erasmus Medisch Centrum ( Site 1621), Rotterdam, Zuid-Holland
Martini Ziekenhuis ( Site 1618), Groningen, Not set
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1709), Siedlce, Mazowieckie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1700), Warszawa, Mazowieckie
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1703), Przemysl, Podkarpackie
Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 1706), Prabuty, Pomorskie
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1707), Bystra, Slaskie
Przychodnia Lekarska KOMED ( Site 1701), Konin, Wielkopolskie
Med-Polonia Sp. z o. o. ( Site 1710), Poznan, Wielkopolskie
Champalimaud Foundation ( Site 1812), Lisbon, Lisboa
Hospital CUF Descobertas ( Site 1815), Lisbon, Lisboa
Centro Hospitalar do Porto - Hospital de Santo António ( Site 1813), Porto, Not set
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1810), Porto, Not set
MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 1905), București, Bucuresti
Centrul medical Focus ( Site 1903), București, Bucuresti
Cardiomed SRL Cluj-Napoca ( Site 1900), Cluj-Napoca, Cluj
Centrul de Oncologie Oncolab-Medical Oncology ( Site 1904), Craiova, Dolj
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1901), Craiova, Dolj
Cabinet Medical Oncomed ( Site 1902), Timisoara, Timis
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2102), Madrid, Madrid, Comunidad De
H.R.U Málaga - Hospital General-Oncology ( Site 2104), Málaga, Malaga
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2100), Barcelona, Not set
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2103), Sevilla, Not set
Ege University Medicine of Faculty-Chest Diseases Department ( Site 2402), Bornova, Izmir
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2407), Adana, Not set
Hacettepe Universitesi-oncology hospital ( Site 2409), Ankara, Not set
Memorial Ankara Hastanesi-Medical Oncology ( Site 2406), Ankara, Not set
Ankara Bilkent City Hospital ( Site 2403), Ankara, Not set
Medipol University Medical Faculty-oncology ( Site 2400), Istanbul, Not set
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2401), Istanbul, Not set
I.E.U. Medical Point Hastanesi-Oncology ( Site 2408), Izmir, Not set
The Christie-Clinical Research Facility ( Site 2607), Manchester, England
Mount Vernon Hospital ( Site 2602), Northwood, Hillingdon
Heartlands Hospital-Oncology Research ( Site 2604), Birmingham, Not set
Conditions: Small Cell Lung Carcinoma
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Active Not Recruiting
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that... Read More
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR).
Osimertinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with osimertinib, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining osimertinib with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer.
In total the study aims to enroll approximately 586 patients, consisting of approximately 30 patients who will participate in a safety run-in component of the trial, and approximately 556 who will receive osimertinib alone or osimertinib in combination with chemotherapy in the main trial. In the main part of the trial there is a one in two chance of receiving osimertinib alone, and the treatment is decided at random by a computer.
The study involves a Screening Period, Treatment Period, and Follow up Period. Whilst receiving study medication, it is expected patients will attend, on average, approximately 15 visits over the first 12 months and then approximately 4 visits per year afterwards. Each visit will last about 2 to 6 hours depending on the arrangement of medical assessments by the study centre. Read Less
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
07/03/2025
Locations: Research Site, Bellflower, California +152 locations
Research Site, Bellflower, California
Research Site, Fullerton, California
Research Site, La Jolla, California
Research Site, Santa Monica, California
Research Site, Santa Rosa, California
Research Site, West Hollywood, California
Research Site, Whittier, California
Research Site, Orlando, Florida
Research Site, Tampa, Florida
Research Site, Kansas City, Kansas
Research Site, Louisville, Kentucky
Research Site, Boston, Massachusetts
Research Site, Henderson, Nevada
Research Site, Albany, New York
Research Site, Canton, Ohio
Research Site, Philadelphia, Pennsylvania
Research Site, Pittsburgh, Pennsylvania
Research Site, Pittsburgh, Pennsylvania
Research Site, Houston, Texas
Research Site, San Antonio, Texas
Research Site, Blacksburg, Virginia
Research Site, Fairfax, Virginia
Research Site, Vancouver, Washington
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, Caba, Not set
Research Site, Ciudad de Buenos Aires, Not set
Research Site, Cordoba, Not set
Research Site, Santa Fe, Not set
Research Site, Camperdown, Not set
Research Site, Chermside, Not set
Research Site, Elizabeth Vale, Not set
Research Site, Heidelberg, Not set
Research Site, Kogarah, Not set
Research Site, Melbourne, Not set
Research Site, Barretos, Not set
Research Site, Florianópolis, Not set
Research Site, Londrina, Not set
Research Site, Porto Alegre, Not set
Research Site, Ribeirão Preto, Not set
Research Site, Sao Paulo, Not set
Research Site, São José do Rio Preto, Not set
Research Site, São Paulo, Not set
Research Site, Vitoria, Not set
Research Site, Calgary, Alberta
Research Site, Edmonton, Alberta
Research Site, Toronto, Ontario
Research Site, Santiago, Not set
Research Site, Santiago, Not set
Research Site, Temuco, Not set
Research Site, Viña del Mar, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Haikou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Harbin, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Urumqi, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Zhengzhou, Not set
Research Site, Olomouc, Not set
Research Site, Ostrava - Vitkovice, Not set
Research Site, Praha 5, Not set
Research Site, Praha, Not set
Research Site, Bordeaux Cedex, Not set
Research Site, Lyon, Not set
Research Site, Montpellier, Not set
Research Site, Villejuif Cedex, Not set
Research Site, Belagavi, Not set
Research Site, Bengaluru, Not set
Research Site, Gurgaon, Not set
Research Site, Kolkata, Not set
Research Site, New Delhi, Not set
Research Site, Pune, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Fukuoka, Not set
Research Site, Hidaka-shi, Not set
Research Site, Himeji-shi, Not set
Research Site, Iwakuni-shi, Not set
Research Site, Kanazawa, Not set
Research Site, Kashiwa, Not set
Research Site, Koto-ku, Not set
Research Site, Osaka-shi, Not set
Research Site, Sakai-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Yokohama-shi, Not set
Research Site, Cheongju-si, Not set
Research Site, Goyang-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Arequipa, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, San Isidro, Not set
Research Site, Cebu City, Not set
Research Site, Davao City, Not set
Research Site, Iloilo City, Not set
Research Site, Las Pinas, Not set
Research Site, Legazpi City, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Murmansk, Not set
Research Site, Saint Petersburg, Not set
Research Site, Saint Petersburg, Not set
Research Site, Saint-Petersburg, Not set
Research Site, Syktyvkar, Not set
Research Site, Bratislava, Not set
Research Site, Kosice, Not set
Research Site, Poprad, Not set
Research Site, Johannesburg, Not set
Research Site, Port Elizabeth, Not set
Research Site, Rondebosch, Not set
Research Site, Changhua, Not set
Research Site, Hualien City, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Hat Yai, Not set
Research Site, Khon Kaen, Not set
Research Site, Muang, Not set
Research Site, Cambridge, Not set
Research Site, Leicester, Not set
Research Site, Liverpool, Not set
Research Site, Maidstone, Not set
Research Site, Manchester, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh, Not set
Conditions: Non-Small Cell Lung Cancer
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Recruiting
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC).
Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemoth... Read More
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC).
Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Lyell McEwin Hospital, Elizabeth Vale, Not set +60 locations
Lyell McEwin Hospital, Elizabeth Vale, Not set
Greenslopes Private Hospital, Greenslopes, Not set
The Alfred Hospital, Melbourne, Not set
Tasman Oncology Research Ltd, Southport, Not set
Calvary Mater Newcastle, Waratah, Not set
Cancer Care Wollongong Pty Limited, Wollongong, Not set
Algemeen Ziekenhuis Maria Middelares, Gent, Not set
Clinique et Maternité Sainte-Elisabeth, Namur, Not set
Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich, Not set
Multiprofile Hospital For Active Treatment "Dr. Tota Venkova" AD, Gabrovo, Not set
MHAT Uni Hospital OOD, Panagyurishte, Not set
Complex Oncology Center Ruse, Ruse, Not set
Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, Not set
Brampton Civic Hospital, Brampton, Not set
Unite de recherche clinique du CISSS des Laurentides, St-Jerome, Not set
Klinički Bolnički Centar Osijek, Osijek, Not set
Klinicka Bolnica Centar - Sestre Milosrdnice - Klinika Za Tumore (University Hospital for Tumors), Zagreb, Not set
Klinički Bolnički Centar Sestre Milosrdnice, Zagreb, Not set
Klinički Bolnički Centar Zagreb - Klinika Za Plućne Bolesti Jordanovac, Zagreb, Not set
Krankenhaus Nordwest, Frankfurt am Main, Not set
Krankenhaus Martha-Maria Halle-Dölau, Halle (Saale), Not set
General Hospital of Athens "Laiko", Athens, Not set
Sotiria Chest Diseases Hospital, Athens, Not set
University of Thessaly- General University Hospital of Larissa, Larissa, Not set
University of Patras - Rio Regional University Hospital, Patras, Not set
Metropolitan Hospital, Department of Oncology, Piraeus, Not set
Bioclinic of Thessaloniki, Thessaloniki, Not set
Interbalkan Medical Center of Thessaloniki, Thessaloniki, Not set
St. Luke's Hospital S.A., Thessaloniki, Not set
HCG Cancer Centre - Double Road (Bangalore Institute of Oncology (BIO)), Bangalore, Not set
Geri Care Hospital T.Nagar, Chennai, Not set
Sunact Cancer Institute Pvt. Ltd., Thane, Not set
Tata Memorial Centre - Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Not set
Beaumont Hospital, Dublin, Not set
Mater Misericordiae University Hospital, Dublin, Not set
Tallaght University Hospital, Dublin, Not set
Azienda Ospedaliera San Giuseppe Moscati, Avellino, Not set
Centro di Riferimento Oncologico (CRO), Aviano, Not set
Istituto per la Ricerca e la Cura del Cancro (IRCC) - Istituto di Candiolo, Candiolo, Not set
Istituto Nazionale Tumori (INT) "Fondazione G. Pascale" di Napoli, Napoli, Not set
Azienda Ospedaliera Santa Maria di Terni, Terni, Not set
Latvian Oncology Center, Riga, Not set
Paula Stradiņa Klīniskā Universitātes Slimnīca, Riga, Not set
Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Not set
Nacionalinis Vezio Institutas, Vilnius, Not set
Instytut Medyczny Santa Familia Sp. z o. o. w Łodzi, Lodz, Not set
IP Clinic Sp. z o.o., Lodz, Not set
Unidade Local de Saude de Santa Maria, EPE - Hospital Pulido Valente, Lisboa, Not set
Centrul Medical Medicover Victoria, Bucharest, Not set
Spitalul Memorial Healthcare International, Bucharest, Not set
Onco Clinic Consult SA, Craiova, Not set
OncoLab, Craiova, Not set
Victoria Hospital - Centrul de Oncologie Euroclinic SRL, Iasi, Not set
Ovidius Clinical Hospital S.R.L., Ovidiu, Not set
Hospital Universitari Germans Trias i Pujol, Badalona, Not set
Hospital de la Santa Creu i Sant Pau, Barcelona, Not set
HM Universitario Sanchinarro, Madrid, Not set
Hospital Regional Universitario de Málaga - Hospital General, Malaga, Not set
Hospital Universitario Central de Asturias, Oviedo, Not set
Parc Tauli Hospital Universitari, Sabadell, Not set
Hospital Clínico Universitario "Lozano Blesa", Zaragoza, Not set
Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Active Not Recruiting
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +215 locations
Mayo Clinic Arizona, Phoenix, Arizona
Marin Cancer Care, Greenbrae, California
UC Irvine Medical Center, Orange, California
Georgetown University-Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Mayo Clinic-Florida, Jacksonville, Florida
Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida
Winship Cancer Institute of Emory University, Atlanta, Georgia
University of Chicago Medical Center, Chicago, Illinois
Parkview Research Center, Fort Wayne, Indiana
University of Iowa Hospital and Clinics, Iowa City, Iowa
The University of Kansas Cancer Center, Westwood, Kansas
Ochsner Clinic Foundation Ocf Ochsner Cancer Institute Oci, New Orleans, Louisiana
Johns Hopkins Oncology Center, Baltimore, Maryland
Boston Medical Center, Boston, Massachusetts
Beth Israel Deaconess Medical Center, Boston, Massachusetts
Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan
Henry Ford Hospital, Detroit, Michigan
Karmanos Cancer Institute, Farmington Hills, Michigan
Mayo Clinic, Rochester, Minnesota
Comprehensive Cancer Centers of Nevada-Twain, Las Vegas, Nevada
Summit Medical Group, Florham Park, New Jersey
Icahn School of Medicine At Mount Sinai, New York, New York
White Plains Hospital, White Plains, New York
University Hospitals Cleveland Medical Center, Cleveland, Ohio
Cleveland Clinic Foundation, Cleveland, Ohio
Providence Portland Med. Ctr, Portland, Oregon
Oregon Health & Science University, Portland, Oregon
Fox Chase Cancer Center, Philadelphia, Pennsylvania
Greenville Hospital System University Medical Center Institute For Translational Oncology Research, Greenville, South Carolina
Baylor Scott and White Research Institute, Dallas, Texas
Houston Methodist Research Institute, Houston, Texas
Riverside Regional Medical Center, Newport News, Virginia
Virginia Commonwealth University, Richmond, Virginia
Virginia Mason Medical Center, Seattle, Washington
West Virginia University Cancer Institute, Morgantown, West Virginia
Aurora Research Institute, Wauwatosa, Wisconsin
Landeskrankenhaus Universitatsklinikum Graz, Graz, Not set
Innsbruck University Hospital, Innsbruck, Not set
Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz, Linz, Not set
Salzburger Universitatsklinikum, Salzburg, Not set
Landeskrankenhaus Steyr, Steyr, Not set
Allgemeines Krankenhaus Der Stadt Wien, Vienna, Not set
Ulb Hospital Erasme, Bruxelles, Not set
Universitair Ziekenhuis Brussel, Bruxelles, Not set
Universitair Ziekenhuis Gent, Gent, Not set
Hospital de Jolimont, Haine-st-paul, Not set
Az Groeninge Campus Kennedylaan, Kortrijk, Not set
Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Not set
Chu Ucl Namur University Hospital Mont-Godinne, Yvoir, Not set
Tom Baker Cancer Centre, Calgary, Alberta
Cancercare Manitoba, Winnipeg, Manitoba
Nova Scotia Health Authority/Qeii Health Sciences Centre, Halifax, Nova Scotia
Princess Margaret Cancer Center, Toronto, Ontario
McGill University Health Centre Research Institute, Montreal, Quebec
Peking Union Medical College Hospital, Beijing, Not set
West China Hospital Sichuan University, Chengdu, Not set
Fujian Cancer Hospital, Fuzhou, Not set
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangdong, Not set
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, Not set
Shulan Hangzhou Hospital Co Ltd, Hangzhou, Not set
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Not set
Heilongjiang Province Cancer Hospital, Harbin, Not set
University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital), Hefei, Not set
Kunming 1St People'S Hospital, Kunming, Not set
Jiangsu Province Hospital, Nanjing, Not set
The Affiliated Hospital of Qingdao University, Shandong, Not set
Zhongshan Hospital Fudan University, Shanghai, Not set
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Not set
Xinhua Hospital, SHanghai, Not set
Sichuan Cancer Hospital, Sichuan, Not set
Tianjin Medical University Cancer Institute Hospital, Tianjin, Not set
Tongji Hospital Huazhong University of Science and Technology, Wuhan, Not set
Hubei Cancer Hospital, Wuhan, Not set
Northern Jiangsu Peoples Hospital, Yangzhou, Not set
Herlev Og Gentofte Hospital, Herlev, Not set
Docrates Cancer Center, Helsinki, Not set
Helsinki University Central Hospital, Helsinki, Not set
Tampere University Hospital, Tampere, Not set
Institut Sainte Catherine, Avignon Cedex 9, Not set
Chu Besancon Hospital Jean Minjoz, Besançon, Not set
Institut Bergonie, Bordeaux Cedex, Not set
Hopital Beaujon, Clichy, Not set
Chu de Limoges - Hospital Dupuytren, Limoges Cedex, Not set
Hopital Prive Jean Mermoz, Lyon Cedex 08, Not set
Chu Hopital de La Timone, Marseille Cedex 5, Not set
Centre Hospitalier Universitaire de Nantes, Nantes, Not set
Centre Antoine Laccassagne, Nice Cedex 02, Not set
Hospital Universitaire Pitie-Salpetriere, Paris Cedex 13, Not set
Hopital Europeen Georges Pompidou (Hegp), Paris Cedex 15, Not set
Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque, Pessac Cedex, Not set
Hospital de La Miletrie, Poitiers Cedex, Not set
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume, Rouen Cedex, Not set
University Hospital of Saint Etienne, Saint Etienne, Not set
Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau, Saint Herblain, Not set
Chu Toulouse Hopital Rangueil, Toulouse Cedex 9, Not set
Chu Vandoeuvre-Les-Nancy Hopital Brabois, Vandoeuvre Les Nancy, Not set
Institut Gustave Roussy, Villejuif Cedex, Not set
University Medical Center Rwth Aachen, Aachen, Not set
Charite - Campus Virchow-Klinikum, Berlin, Not set
Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin, Not set
Universitatsklinikum Bonn Aoer, Bonn, Not set
Klinikum Bremen-Nord, Bremen, Not set
University Clinic Carl Gustav Carus Technical University Dresden, Dresden, Not set
Klinikum Der Johann Wolfgang Goethe University, Frankfurt Am Main, Not set
University Medical Center Freiburg, Freiburg, Not set
Universitatsklinikum Hamburg Eppendorf, Hamburg, Not set
Asklepios Klinik Altona, Hamburg, Not set
Hannover Medical School, Hannover, Not set
Universitaetsklinikum Des Saarlandes, Homburg / Saar, Not set
Universitatsklinikum Koln, Koln, Not set
Universitatsklinikum Leipzig Aor, Leipzig, Not set
Klinikum Ludwigsburg, Ludwigsburg, Not set
Otto-Von-Guericke-Universitat Magdeburg, Magdeburg, Not set
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, Not set
University Hospital Grosshadern Munich, Munich, Not set
Klinikum Nuernberg, Nuernberg, Not set
Universitaetsklinikum in Tubingen, Tubingen, Not set
University Hospital Tuebingen, Tubingen, Not set
Universitatkinikums Ulm, ULM, Not set
St. Vincent'S University Hospital, Dublin 4, Not set
Soroka University Medical Center, Beer-sheva, Not set
Rambam Health Care Campus, Haifa, Not set
Hadassah University Hospital, Jerusalem, Not set
Rabin Medical Center - Beilinson Hospital, Petach Tikva, Not set
Tel Aviv Sourasky Medical Center, Tel Aviv, Not set
Azienda Ospedaliero Universitaria Delle Marche, Ancona, Not set
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, Not set
Ospedale Papa Giovanni Xxiii, Bergamo, Not set
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Not set
Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo, Candiolo, Not set
Presidio Ospedaliero Garibaldi Nesima, Catania, Not set
Ospedale Degli Infermi - Faenza, Faenza, Not set
Irccs Azienda Ospedaliera Universitaria San Martino, Genova, Not set
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano, Milano, Not set
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan, Not set
European Institute of Oncology, Milan, Not set
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Not set
A.O.U. Di Modena - Policlinico, Modena, Not set
Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli, Not set
Universita Degli Studi Della Campania Luigi Vanvitelli U.O.C. Oncologia Medica, Napoli, Not set
Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Orbassano, Not set
Iov - Istituto Oncologico Veneto Irccs, Padova, Not set
Presidio Ospedaliero Pescara, Pescara, Not set
Azienda Ospedaliera Universitaria Pisana, Pisa, Not set
Fondazione Policlinico Universitario Agostino Gemelli Irccs, Roma, Not set
Istituto Nazionale Tumori Regina Elena Irccs, Roma, Not set
Universita Campus Bio Medico Di Roma, Rome, Not set
Azienda Ospedaliera San Camillo Forlanini, Rome, Not set
Irccs Istituto Clinico Humanitas, Rozzano, Not set
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte, Siena, Not set
Centro Ricerche Cliniche Di Verona (Crc), Verona, Not set
San Bartolo Hospital, Vicenza, Not set
University of Tokyo Hospital, Bunkyo, Not set
Chiba Cancer Center, Chiba-shi, Not set
Chiba University Hospital, Chiba, Not set
Kyushu University Hospital, Fukuoka-shi, Not set
National Hospital Organization Kyushu Cancer Center, Fukuoka, Not set
Hiroshima University Hospital, Hiroshima-shi, Not set
Hyogo College of Medicine Hospital, Hyogo, Not set
Kanazawa University Hospital, Ishikawa, Not set
Teikyo University Hospital, Itabashi-ku, Not set
Kobe University Hospital, Kobe-shi, Not set
Cancer Institute Hospital of Jfcr, Koto-ku, Not set
Kyoto University Hospital, Kyoto-shi, Not set
Nho Shikoku Cancer Center, Matsuyama-shi, Not set
Kyorin University Hospital, Mitaka-shi, Not set
Aichi Cancer Center Hospital, Nagoya-shi, Not set
Niigata Cancer Center Hospital, Niigata, Not set
Osaka International Cancer Institute, Osaka-shi, Not set
Kindai University Hospital, Osakasayama City, Not set
Saitama Cancer Center, Saitama, Not set
Hokkaido University Hospital, Sapporo-shi, Not set
Tohoku University Hospital, Sendai-shi, Not set
Jichi Medical University Hospital, Shimotsuke-shi, Not set
Keio University Hospital, Shinjuku-ku, Not set
Shizuoka Cancer Center, Shizuoka, Not set
Osaka University Hospital, Suita-shi, Not set
Toyama University Hospital, Toyama-shi, Not set
Yamaguchi University Hospital, UBE, Not set
Wakayama Medical University Hospital, Wakayama, Not set
Yokohama City University Medical Center, Yokohama-shi, Not set
Kanagawa Cancer Center, Yokohama-shi, Not set
Oita University Hospital, Yufu-shi, Not set
Amsterdam University Medical Centre, Amsterdam, Not set
Maastricht Umc+, Maastricht, Not set
Erasmus Medical Center, Rotterdam, Not set
Umc Utrecht, Utrecht, Not set
Oslo University Hospital, Oslo, Not set
Hospital de La Santa Creu I Sant Pau, Barcelona, Not set
Hospital General Universitario Vall D Hebron, Barcelona, Not set
Hospital Clinic Barcelona Main, Barcelona, Not set
Hospital Universitario Reina Sofia, Cordoba, Not set
Hospital Universitario Reina Sofia, Córdoba, Not set
Hospital Materno Teresa Herrera, La Coruña, Not set
Hospital General Universitario Gregorio Maranon, Madrid, Not set
Hospital Universitario Ramon Y Cajal, Madrid, Not set
Hospital Universitario Hm Sanchinarro, Madrid, Not set
Hospital Regional Universitario de Malaga, Málaga, Not set
Clinica Universidad de Navarra (Cun), Pamplona, Not set
Hospital Universitari Parc Tauli, Sabadell, Not set
HOSPITAL UNiVERSITARIO DONOSTIA, San Sebastian, Not set
Hospital Universitario Marques de Valdecilla, Santander, Not set
Hospital General Universitario de Valencia, Valencia, Not set
Karolinska Institute Universitetssjukhuset Solna, Solna, Not set
Inselspital - Universitaetsspital Bern, Bern, Not set
Universitatsspital Zurich, Zuerich, Not set
Aberdeen Royal Infirmary, Aberdeen, Not set
Addenbrookes Hospital, Cambridge, Not set
Velindre Cancer Centre, Cardiff, Not set
University Hospital Coventry and Warwickshire, Coventry, Not set
The Royal Marsden Nhs Foundation Trust - Chelsea, London, Not set
Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London, Not set
University College London Hospitals (Uclh), London, Not set
Kent Oncology Centre - Maidstone Hospital, Maidstone, Not set
The Christie Nhs Foundation Trust, Manchester, Not set
The Royal Marsden Nhs Foundation Trust - Sutton, Sutton, Not set
Conditions: Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Active Not Recruiting
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements). Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Phoenix, Arizona +255 locations
Research Site, Phoenix, Arizona
Research Site, Tucson, Arizona
Research Site, Hot Springs National Park, Arkansas
Research Site, Little Rock, Arkansas
Research Site, Springdale, Arkansas
Research Site, Fountain Valley, California
Research Site, Los Angeles, California
Research Site, Orange, California
Research Site, Boulder, Colorado
Research Site, Fort Myers, Florida
Research Site, Jacksonville, Florida
Research Site, Lakeland, Florida
Research Site, Saint Petersburg, Florida
Research Site, West Palm Beach, Florida
Research Site, Hinsdale, Illinois
Research Site, Fort Wayne, Indiana
Research Site, Bettendorf, Iowa
Research Site, Des Moines, Iowa
Research Site, Iowa City, Iowa
Research Site, Baton Rouge, Louisiana
Research Site, Covington, Louisiana
Research Site, Duluth, Minnesota
Research Site, Rochester, Minnesota
Research Site, Hannibal, Missouri
Research Site, Lincoln, Nebraska
Research Site, Lincoln, Nebraska
Research Site, Clifton Park, New York
Research Site, Asheville, North Carolina
Research Site, Canton, Ohio
Research Site, Columbus, Ohio
Research Site, Maumee, Ohio
Research Site, Tulsa, Oklahoma
Research Site, Portland, Oregon
Research Site, Salem, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Philadelphia, Pennsylvania
Research Site, Philadelphia, Pennsylvania
Research Site, York, Pennsylvania
Research Site, Watertown, South Dakota
Research Site, Memphis, Tennessee
Research Site, Dallas, Texas
Research Site, Fort Worth, Texas
Research Site, Houston, Texas
Research Site, Houston, Texas
Research Site, Irving, Texas
Research Site, Fairfax, Virginia
Research Site, Henrico, Virginia
Research Site, Norfolk, Virginia
Research Site, Renton, Washington
Research Site, Spokane, Washington
Research Site, Tacoma, Washington
Research Site, Appleton, Wisconsin
Research Site, La Crosse, Wisconsin
Research Site, Graz, Not set
Research Site, Rankweil, Not set
Research Site, Wien, Not set
Research Site, Wien, Not set
Research Site, Blumenau, Not set
Research Site, Florianópolis, Not set
Research Site, Fortaleza, Not set
Research Site, Londrina, Not set
Research Site, Porto Alegre, Not set
Research Site, Sao Paulo, Not set
Research Site, Sao Paulo, Not set
Research Site, Sao Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Taubaté, Not set
Research Site, Vitoria, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Saint John, New Brunswick
Research Site, Brampton, Ontario
Research Site, Kitchener, Ontario
Research Site, Newmarket, Ontario
Research Site, Sudbury, Ontario
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, St-Jerome, Quebec
Research Site, Saskatoon, Saskatchewan
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Kunming, Not set
Research Site, Lanzhou, Not set
Research Site, Liuzhou, Not set
Research Site, Shandong, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shantou, Not set
Research Site, Shenyang, Not set
Research Site, Shenzhen, Not set
Research Site, Taiyuan, Not set
Research Site, Tianjin, Not set
Research Site, Wenzhou, Not set
Research Site, Wuhan, Not set
Research Site, Wuhan, Not set
Research Site, Xiamen, Not set
Research Site, Yangzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Brest, Not set
Research Site, Creteil, Not set
Research Site, Gleize, Not set
Research Site, Montpellier, Not set
Research Site, Nimes, Not set
Research Site, Paris CEDEX 14, Not set
Research Site, Paris, Not set
Research Site, Rouen, Not set
Research Site, Saint-Quentin, Not set
Research Site, Strasbourg Cedex, Not set
Research Site, Toulon Cedex 9, Not set
Research Site, Toulouse, Not set
Research Site, Tours, Not set
Research Site, Bad Berka, Not set
Research Site, Berlin, Not set
Research Site, Frankfurt A. Main, Not set
Research Site, Gauting, Not set
Research Site, Gütersloh, Not set
Research Site, Hamburg, Not set
Research Site, Kassel, Not set
Research Site, Kiel, Not set
Research Site, Koblenz, Not set
Research Site, Minden, Not set
Research Site, Rosenheim, Not set
Research Site, Velbert, Not set
Research Site, Würzburg, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Peiraias, Not set
Research Site, Thessaloniki, Not set
Research Site, Thessaloniki, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Gyöngyös - Mátraháza, Not set
Research Site, Kaposvár, Not set
Research Site, Pécs, Not set
Research Site, Szekszárd, Not set
Research Site, Szolnok, Not set
Research Site, Törökbálint, Not set
Research Site, Calicut, Not set
Research Site, Delhi, Not set
Research Site, Delhi, Not set
Research Site, Jaipur, Not set
Research Site, Kolkata, Not set
Research Site, Madurai, Not set
Research Site, Puducherry, Not set
Research Site, Firenze, Not set
Research Site, Lecco, Not set
Research Site, Messina, Not set
Research Site, Napoli, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Parma, Not set
Research Site, Peschiera Del Garda, Not set
Research Site, Rozzano, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Hamamatsu-shi, Not set
Research Site, Hamamatsu-shi, Not set
Research Site, Hidaka-shi, Not set
Research Site, Hirosaki-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Wakayama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Busan, Not set
Research Site, Cheongju-si, Not set
Research Site, Jinju-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon-si, Not set
Research Site, Suwon, Not set
Research Site, Cdmx, Not set
Research Site, Del. Cuauhtemoc, Not set
Research Site, Mexico, Not set
Research Site, San Luis Potosí, Not set
Research Site, Arequipa, Not set
Research Site, Concepción, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Bydgoszcz, Not set
Research Site, Bystra, Not set
Research Site, Grudziądz, Not set
Research Site, Kielce, Not set
Research Site, Koszalin, Not set
Research Site, Olsztyn, Not set
Research Site, Poznań, Not set
Research Site, Przemysl, Not set
Research Site, Racibórz, Not set
Research Site, Radom, Not set
Research Site, Siedlce, Not set
Research Site, Las Palmas de Gran Canaria, Not set
Research Site, Lugo, Not set
Research Site, Madrid, Not set
Research Site, Santander, Not set
Research Site, Sevilla, Not set
Research Site, Valencia, Not set
Research Site, Zaragoza, Not set
Research Site, Gävle, Not set
Research Site, Linköping, Not set
Research Site, Lund, Not set
Research Site, Stockholm, Not set
Research Site, Uppsala, Not set
Research Site, Hsinchu, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan City, Not set
Research Site, Adana, Not set
Research Site, Ankara, Not set
Research Site, Edirne, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Aberdeen, Not set
Research Site, Cambridge, Not set
Research Site, Cardiff, Not set
Research Site, Cheltenham, Not set
Research Site, Edinburgh, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Middlesborough, Not set
Research Site, Newcastle-Upon-Tyne, Not set
Research Site, Taunton, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh city, Not set
Research Site, Ho Chi Minh, Not set
Conditions: NSCLC
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Active Not Recruiting
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Pacific Cancer Medical Center, Anaheim, California +72 locations
Pacific Cancer Medical Center, Anaheim, California
UC Davis Comprehensive Cancer Center, Sacramento, California
St. Joseph Heritage Healthcare, Santa Rosa, California
University of Colorado Cancer Center, Aurora, Colorado
Yale Cancer Center, New Haven, Connecticut
Northwest Georgia Oncology Centers PC, Douglasville, Georgia
U of Kansas Cancer Center, Westwood, Kansas
Baptist Health, Louisville, Kentucky
St. Vincent Healthcare Cancer Ctr, Billings, Montana
New Mexico Cancer Care Alliance, Albuquerque, New Mexico
Oklahoma Cancer Specialists and Research, Tulsa, Oklahoma
Providence Portland Med Center, Portland, Oregon
Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah
Viginia Mason Med Ctr, Seattle, Washington
Chris OBrien Lifehouse, Camperdown, New South Wales
Macquarie University Hospital, North Ryde, New South Wales
Royal Brisbane & Women s Hospital, Herston, Queensland
Landeskrankenhaus Salzburg, Salzburg, Not set
Allgemeines Krankenhaus der Stadt Wien, Wien, Not set
Juravinski Cancer Center Hamilton Health Sciences, Hamilton, Ontario
Princess Margaret Cancer Centre, Toronto, Ontario
Jewish General Hospital, Montreal, Quebec
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec, Quebec, Not set
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Not set
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok, Not set
Istituto Europeo di Oncologia, Milano, Not set
IRRCS Instituto Clinico Humanitas, Rozzano, Not set
National Cancer Center Hospital East, Kashiwa, Chiba
Kanazawa University Hospital, Kanazawa, Ishikawa
Kanagawa Cancer Center, Yokohama, Kanagawa
Miyagi Cancer Center, Natori, Miyagi
Tohoku University Hospital, Sendai, Miyagi
Hyogo Cancer Center, Akashi, Not set
Kyushu University Hospital, Fukuoka, Not set
Hiroshima University Hospital, Hiroshima, Not set
Hokkaido University Hospital, Hokkaido, Not set
Kobe City Medical Center General Hospital, Kobe, Not set
Kindai University Hospital, Osakasayama City, Not set
Saitama Cancer Center, Saitama, Not set
Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, Not set
The Cancer Institute Hospital of JFCR, Tokyo, Not set
Seoul National University Hospital, Seoul, Not set
Severance Hospital Yonsei University Health System, Seoul, Not set
Asan Medical Center, Seoul, Not set
Mazowiecki Szpital Onkologiczny, Wieliszew, Mazowieckie
Przychodnia Lekarska Komed, Konin, Not set
Zachodniopomorskie Centrum Onkologii, Szczecin, Not set
Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE, Coimbra, Not set
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisboa, Not set
Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisboa, Not set
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE, Porto, Not set
Hospital Germans Trias i Pujol. ICO de Badalona, Badalona, Not set
Hospital General Universitari Vall d Hebron, Barcelona, Not set
Hospital Ramon y Cajal, Madrid, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Infanta Cristina, Madrid, Not set
Hospital de Nuestra Senora de Valme, Sevilla, Not set
Hospital Clinico Lozano Blesa, Zaragoza, Not set
National Cheng Kung University Hospital, Tainan, Not set
National Taiwan University Hospital, Taipei, Not set
Chang Gung Medical Foundation. Linkou, Taoyuan, Not set
Adana Sehir Hastanesi, Adana, Not set
Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Not set
Trakya Universitesi Tip Fakultesi, Edirne, Not set
Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Not set
Medipol Hastanesi, Istanbul, Not set
Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Not set
Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya, Not set
North Middlesex Hospital, London, Not set
University College London Hospitals (UCLH), London, Not set
The Royal Marsden Foundation Trust, London, Not set
The Royal Marsden Nhs Foundation Trust - Chelsea, London, Not set
Musgrove Park Hospital, Taunton, Not set
Conditions: Head and Neck Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Southern Cancer Center Pc, Daphne, Alabama +246 locations
Southern Cancer Center Pc, Daphne, Alabama
Ironwood Cancer and Research Centers, Chandler, Arizona
Arizona Oncology Associates, Pc - Nahoa, Prescott Valley, Arizona
Hoag Memorial Hospital Prebyterian, Newport Beach, California
Compassionate Cancer Care Medical Group, Riverside, California
Sansum Clinic, Santa Barbara, California
Ronald Reagan UCLA Medical Center, Santa Monica, California
UCHealth Memorial Hospital, Colorado Springs, Colorado
Florida Cancer Specialists - South, Fort Myers, Florida
Cancer Specialist of North Florida, Jacksonville, Florida
Cancer Care Centers of Brevard, Inc., Palm Bay, Florida
Woodlands Medical Specialists, Pa, Pensacola, Florida
Florida Cancer Specialists-North, Saint Petersburg, Florida
Emory University - Winship Cancer Institute Wci, Atlanta, Georgia
Illinois Cancer Specialists, Niles, Illinois
American Oncology Partners of Maryland, Bethesda, Maryland
Maryland Oncology Heamtology P.A., Columbia, Maryland
Beth Israel Deaconess Medical Center, Boston, Massachusetts
Dana Farber Cancer Institute; Inv Drg Svc Pharm, Boston, Massachusetts
Dana Farber Cancer Institute At St. Elizabeth'S Medical Center, Brighton, Massachusetts
Dana Farber Brigham Cancer Center, Foxboro, Massachusetts
Dana Farber At Milford Regional Cancer Center, Milford, Massachusetts
Dana Farber/Bwcc in Affiliation With South Shore Hospital, South Weymouth, Massachusetts
Astera Cancer Care, East Brunswick, New Jersey
Regional Cancer Care Associates LLC, Hackensack, New Jersey
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx, Bronx, New York
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park, New Hyde Park, New York
North Shore Hematology Oncology Associates, Patchogue, New York
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York
Texas Oncology, P.A., McAllen, Texas
Ut Health San Antonio, San Antonio, Texas
Texas Oncology, P.A., Sugar Land, Texas
Texas Oncology-Tyler, Tyler, Texas
Utah Cancer Specialists IHO Corp, Salt Lake City, Utah
Providence Regional Cancer System, Lacey, Washington
VA Puget Sound Health Care System, Seattle, Washington
Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, Not set
Fundacion CENIT para la investigacion en Neurociencias, Ciudad Autonoma de Buenos Aire, Not set
Hospital de La Comunidad, Mar del Plata, Not set
Centro de Investigacion Pergamino Sa, Pergamino, Not set
Instituto de Oncologia de Rosario, Rosario, Not set
Sanatorio Parque, Rosario, Not set
Centro Polivalente de Asistencia E Investigacion Clinica Cer San Juan, San Juan, Not set
Centro de Investigaciones Clinicas. Clinica Viedma S.A., Viedma, Not set
CRSA/ St Andrews Hospital, Adelaide, Not set
Flinders Medical Centre (Fmc), Bedford Park, Not set
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group), Frankston, Not set
St George Public Hospital, Kogarah, Not set
Southern Medical Day Care Centre, Wollongong, Not set
Princess Alexandra Hospital, Woolloongabba, Not set
Landeskrankenhaus Feldkirch, Feldkirch, Not set
Klinikum Klagenfurt Pulmologie, Klagenfurt, Not set
Karl Landsteiner Institut Fã¼R Lungenforschung Und Pneumologische Onkologie C/O Klinik Floridsdorf, Vienna, Not set
Az Maria Middelares - Campus Maria Middelares, Gent, Not set
Centre hospitalier Jolimont-Lobbes, Haine Saint-Paul, Not set
Jessa Hospital, Hasselt, Not set
Cliniques Saint Pierre Ottignies (CSPO), Ottignies, Not set
Az Nikolaas, Sint-Niklaas, Not set
Personal Oncologia de Precisao - Cenantron, Belo Horizonte, Not set
Fundaco Universidade de Caxias Do Sul- Instituto de Pesquisas Em Saude Ips-Ucs, Caxias do Sul, Not set
Hospital Erasto Gaertner, Curitiba, Not set
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Not set
Clínica de Neoplasias Litoral Ltda, ItajaĂ-, Not set
Clnica Lacks, Pelotas, Not set
Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Not set
Instituto Nacional de Că'Ncer - Inca, Rio de Janeiro, Not set
Centro de Estudos E Pesquisa de Hematologia E Oncologia - Cepho, Santo Andre, Not set
Instituto de Ensino E Pesquisa Sao Lucas, Sao Paulo, Not set
Instituto Do Cancer Brasil - Unidade Taubate, Taubate, Not set
CHU de Quebec -Universite Laval Hopital de L'Enfant-Jesus, Quebec City, Not set
Centro de Estudios Clinicos Saga Spa, Santiago de Chile, Not set
ONCOVIDA, Santiago, Not set
Orlandi Oncologia, Santiago, Not set
Oncocentro Apys, Vina Del Mar, Not set
Centro de Investigaciones Clinicas Vina Del Mar, ViĂąa Del Mar, Not set
Peking University Cancer Hospital Beijing Cancer Hospital Beijing Institute For Cancer Research, Beijing Sheng, Not set
Peking University Peoples Hospital, Beijing, Not set
Cangzhou Peoples Hospital, Cangzhou, Not set
First Affiliated Hospital of Medical College of Jilin University, Changchun, Not set
Jilin Cancer Hospital, Changchun, Not set
Hunan Cancer Hospital, Changsha, Not set
University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute SIC, Chengdu, Not set
Chongqing University Cancer Hospital, Chongqing, Not set
Fujian Medical University - Union Hospital Foochow Christian Union Hospital, Fuzhou, Not set
The First Affiliated Hospital Sun Yat-Sen University, Guangzhou, Not set
Affiliated Cancer Hospital and Insititute of Guangzhou Medical University, Guangzhou, Not set
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Not set
Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Not set
The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou, Not set
Harbin Medical University Cancer Hospital, Harbin, Not set
Inner Mongolia Medical University- the Affiliated Hospital, Hohhot, Not set
Jiamusi Cancer Hospital, Jiamusi, Not set
Linyi Cancer Hospital, Linyi, Not set
The First Affiliated Hospital of Nanchang University, Nanchang, Not set
Zhongda Hospital, Southeast University, Nanjing, Not set
Shanghai Chest Hospital, Shanghai, Not set
Fudan University Shanghai Cancer Center, Shanghai, Not set
Liaoning Cancer Hospital & Institute, Shenyang, Not set
Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Not set
The First Affiliate Hospital of Xi'An Jiaotong University, Xi'an, Not set
Xiangyang Central Hospital, Xianyang, Not set
Henan Cancer Hospital, Zhengzhou, Not set
The First Affiliated Hosptial of Xinjiang Medical University, Ürümqi, Not set
FN Brno Klinika Nemoci Plicnich a TBC, Brno, Not set
Fakultni nemocnice Olomouc FNOL, Olomouc, Not set
Sainte-Catherine Institut du Cancer Avignon-Provence, Avignon, Not set
Hopital Jean Minjoz - CHU de Besancon, Besancon, Not set
Chu de Bordeaux - Hopital Saint Andre, Bordeaux, Not set
Centre Hospitalier Universitaire, CHU, de Poitiers, France, Not set
Hopital Lyon Sud, Lyon, Not set
Centre Leon Berard, Lyon, Not set
Aphm - Hopital Nord, Marseille Cedex 20, Not set
Institut Paoli Calmettes, Marseille, Not set
Chu de Montpellier, Montpellier Cedex 5, Not set
Chu de Nantes, Nantes, Not set
Hopital Prive Du Confluent, Nantes, Not set
Institut Curie, Paris Cedex 05, Not set
Tenon Hospital, Paris, Not set
CHU de Rennes - Hopital Pontchaillou, Rennes, Not set
Hôpital Foch, Suresnes, Not set
Evangelische Lungenklinik Berlin, Berlin, Not set
Klinikum Chemnitz, Chemnitz, Not set
Universitaetsklinikum Essen, Essen, Not set
Klinikum Esslingen Gmbh, Esslingen, Not set
Universitaetsklinikum Freiburg, Freiburg, Not set
University Hospital Giessen, ZIM IV, Giessen, Not set
External pharmacy Fortuna Herstellung GmbH of main site Universitaetsmedizin Mannheim, Mannheim, Not set
University Hospital Mă Nster, Muenster, Not set
Ludwig-Maximilians University Hospital of Munich, Munich, Not set
Sotiria General Hospital of Chest Diseases, Athens, Not set
Metropolitan Hospital - Athens, Athens, Not set
University General Hospital of Heraklion, Heraklion, Not set
University Hospital of Ioannina Uhi, Ioannina, Not set
Metropolitan Hospital, Neo Faliro, Not set
Olympion Hospital, Patras, Not set
Euromedica General Clinic of Thessaloniki, Thessaloniki, Not set
St. Luke's Hospital, Thessaloniki, Not set
Bioclinic Thessaloniki (Galinos Clinic), Thessalonki, Not set
Tuen Mun Hospital, Hong Kong, Not set
Prince of Wales Hospital / The Chinese University of Hong Kong, Hong Kong, Not set
Queen Mary Hospital, Pok Fu Lam, Not set
National Koranyi Institute For Pulmonology, Budapest, Not set
Veszprem Megyei Tudogyogyintezet Farkasgyepu, Farkasgyepu, Not set
Bkmk Hospital, KecskemĂŠt, Not set
Fejer Megyei Szent Gyorgy Korhaz Pulmonologiai Osztaly, Szekesfehervar, Not set
Hetenyi G Korhaz, Onkologiai Kozpont, Szolnok, Not set
Reformatus Pulmonologiai Centrum, Torokbalint, Not set
Istituto Di Candiolo Irccs, Candiolo, Not set
Ospedale San Luca, Lucca, Not set
Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano, Not set
IFO Regina Elena, Rome, Not set
Ospedale S. Maria Della Misericordia, Udine, Not set
Asst Sette Laghi, Varese, Not set
Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Roma Crc - Centro Ricerche Clinich, Verona, Not set
NHO Shikoku Cancer Center, Ehime, Not set
Kurume University Hospital, Fukoka, Not set
Kyushu Cancer Center, Fukuoka, Not set
Kyushu University Hospital, Fukuoka, Not set
Teine Keijinkai Hospital, Hokkaido, Not set
Hyogo Medical University Hospital, Hyogo, Not set
Kanazawa University Hospital, Ishikawa, Not set
Kanagawa Cancer Center, Kanagawa, Not set
Kitasato University hospital, Kanagawa, Not set
Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital, Kumamoto, Not set
University Hospital Kyoto Prefectual University of Medicine, Kyoto, Not set
Matsusaka Municipal Hospital, Mie, Not set
Sendai Kousei Hospital, Miyagi, Not set
Niigata Cancer Center Hospital, Niigata, Not set
Osaka International Cancer Institute, Osaka, Not set
Osaka Toneyama Medical Center, Osaka, Not set
Kansai Medical University Hospital, Osaka, Not set
NHO Kinki-Chuo Chest Medical Center, Osaka, Not set
Dokkyo Medical University Hospital, Tochigi, Not set
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Not set
Juntendo University Hospital, Tokyo, Not set
The Cancer Institute Hospital of JFCR, Tokyo, Not set
Toho University Omori Medical Center, Tokyo, Not set
Iwakuni Clinical Center, Yamaguchi, Not set
Yamaguchi-Ube Medical Center, Yamaguchi, Not set
Yamanashi Prefectural Central Hospital, Yamanashi, Not set
Chungbuk National University Hospital, Cheongjusi, Not set
Kyungpook National University Chilgok Hospital, Daegu, Not set
Samsung Medical Center, Gangnam-Gu, Not set
National Cancer Center, Goyang-si, Not set
Gyeongsang National University Hospital, Jinju-si Gyeongsangnam-do, Not set
Seoul National University Bundang Hospital, Seongnam-si, Not set
Asan Medical Center, Seoul, Not set
Yonsei University Health System - Severance Hospital, Seoul, Not set
The Catholic Univ. of Korea, Seoul St. Marys Hospital, Seoul, Not set
Cryptex Investigacion Clinica Sa de Cv, Cuauhtemoc, Not set
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Not set
Instituto Nacional de Cancerologia, Mexico City, Not set
Centro de Investigacion Clinica de Oaxaca CICLO, Oaxaca, Not set
Amphia Ziekenhuis, Breda, Not set
Leiden University Medical Center, Leiden, Not set
Jeroen Bosch Ziekenhuis Jbz, s-Hertogenbosch, Not set
II Klinika Chorob Pluc i Gruzlicy, Bialystok, Not set
Centrum Terapii Wspolczesnej, Lodz, Not set
Instytut Centrum Zdrowia Matki Polki (Iczmp), Lodz, Not set
SPSK4, Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Not set
Med Polonia Sp. Z O.O., Poznan, Not set
Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Not set
Fundacao Champalimaud, Lisbon, Not set
IPO Porto Francisco Gentil, E.P.E., Porto, Not set
Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj- Napoca, Not set
Onco Clinic Consult Sa, Craiova, Not set
Centrul de Oncologie Sfantu Nectarie, Craiova, Not set
SC Oncomed SRL, Jud Timis, Not set
Oncocenter Oncologie Clinica S.R.L, Timisoara, Not set
Vall Hebron University Hospital, Barcelona, Not set
Hospital Clinic I Provincial de Barcelona, Barcelona, Not set
Hospital Universitario Arnau de Vilanova, Lleida, Not set
Hospital General Universitario Gregorio Marañon, Madrid, Not set
Hospital Clinico San Carlos, Madrid, Not set
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set
Hospital Regional Universitario Malaga, Malaga, Not set
CHUO, Ourense, Not set
Hosp Univ Virgen Macarena, Sevilla, Not set
Hospital Universitario Virgen de Valme, Sevilla, Not set
Hospital Universitario y Politecnico de La Fe, Valenica, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
Kantonsspital Baselland, Liestal, Not set
Kantonsspital St. Gallen, St. Gallen, Not set
Spital Sts Ag, Thun, Not set
Changhua Christian Hospital, Changhua, Not set
China Medical University Hospital, Hsia, Not set
Taichung Veterans General Hospital, Taichung, Not set
National Cheng Kung University Hospital, Tainan, Not set
National Taiwan University Hospital, Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set
Taipei Veterans General Hospital, Taipei, Not set
Tri-Service General Hospital, Taipei, Not set
Linkou Chang Gung Memorial Hospital, Taoyuan, Not set
Faculty of Medicine Chulalongkorn University, Bangkok, Not set
Ramathibodi Hospital, Bangkok, Not set
Siriraj Hospital, Bangkok, Not set
Chiang Mai University CMU - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital, Chiang Mai, Not set
Prince of Songkla University PSU - Faculty of Medicine, Hat Yai, Not set
Khon Kaen University - Faculty of Medicine-Srinagarind Hospital, Mueang Nonthaburi, Not set
Baskent University, Adana, Not set
Ankara Bilkent City Hospital, Ankara, Not set
Akdeniz University Hospital, Antalya, Not set
Medipol Mega University Hospital, Bağcılar, Not set
Memorial Ankara Hospital, Cankaya/Ankara, Not set
Istanbul Medeniyet University Medical Faculty, Istanbul, Not set
Adana Acibadem Hospital, Seyhan, Not set
Barts Health NHS Trust, London, Not set
Conditions: Metastatic Non Small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Completed
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
The primary study hypotheses are that:
* Neoadjuvant and adjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab is superior to neoadjuvant and adjuvant placebo plus chemotherapy, followed by adjuvant placebo in terms of Eve... Read More
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
The primary study hypotheses are that:
* Neoadjuvant and adjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab is superior to neoadjuvant and adjuvant placebo plus chemotherapy, followed by adjuvant placebo in terms of Event-free Survival (EFS) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), and
* Neoadjuvant pembrolizumab plus chemotherapy is superior to neoadjuvant placebo plus chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.
With Amendment 10, upon study completion, participants will be discontinued and may be enrolled in an extension study. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: City of Hope ( Site 0005), Duarte, California +170 locations
City of Hope ( Site 0005), Duarte, California
Yale Cancer Center ( Site 0016), New Haven, Connecticut
Georgetown University ( Site 0015), Washington, District of Columbia
Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0018), Chicago, Illinois
The University of Chicago Medical Center ( Site 0004), Chicago, Illinois
Roswell Park Cancer Institute ( Site 0001), Buffalo, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0019), New York, New York
Memorial Sloan Kettering ( Site 0024), New York, New York
Weill Cornell Medical Center ( Site 0023), New York, New York
University of Rochester ( Site 0011), Rochester, New York
Fox Chase Cancer Center ( Site 0006), Philadelphia, Pennsylvania
Temple University Hospital ( Site 0026), Philadelphia, Pennsylvania
University of Utah, Huntsman Cancer Institute ( Site 0012), Salt Lake City, Utah
Virginia Cancer Specialists, PC ( Site 0010), Fairfax, Virginia
Institut Jules Bordet ( Site 0480), Brussels, Bruxelles-Capitale, Region De
Hopital Erasme ULB ( Site 0484), Brussels, Bruxelles-Capitale, Region De
UCL Saint Luc ( Site 0479), Bruxelles, Bruxelles-Capitale, Region De
Grand Hopital de Charleroi ( Site 0478), Charleroi, Hainaut
CHU de Liege ( Site 0482), Liège, Liege
CHU UCL Namur Site de Godinne ( Site 0485), Yvoir, Namur
UZ Gent ( Site 0486), Gent, Oost-Vlaanderen
UZ Leuven ( Site 0483), Leuven, Vlaams-Brabant
AZ Groeninge ( Site 0481), Kortrijk, West-Vlaanderen
Instituto do Cancer do Ceara ( Site 0311), Fortaleza, Ceara
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0308), Porto Alegre, Rio Grande Do Sul
CEPON - Centro de Pesquisas Oncologicas ( Site 0302), Florianopolis, Santa Catarina
Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0301), Barretos, Sao Paulo
Hospital de Base de Sao Jose de Rio Preto ( Site 0304), Sao Jose Rio Preto, Sao Paulo
Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0307), Rio de Janeiro, Not set
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0305), Sao Paulo, Not set
Hospital Israelita Albert Einstein ( Site 0309), Sao Paulo, Not set
Cross Cancer Institute ( Site 0033), Edmonton, Alberta
Moncton Hospital - Horizon Health Network ( Site 0038), Moncton, New Brunswick
Sunnybrook Research Institute ( Site 0032), Toronto, Ontario
CISSS de la Monteregie-Centre ( Site 0039), Greenfield Park, Quebec
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0040), Montreal, Quebec
Jewish General Hospital ( Site 0034), Montreal, Quebec
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0035), Sherbrooke, Quebec
CHU de Quebec - Hotel-Dieu de Quebec ( Site 0042), Quebec, Not set
Instituto Clinico del Sur. ICOS ( Site 0290), Temuco, Araucania
Hospital Regional Rancagua Libertador Bernardo O Higgins ( Site 0299), Rancagua, Lbtdr Gen Bernardo O Higgins
Fundacion Arturo Lopez Perez FALP ( Site 0286), Santiago, Region M. De Santiago
Pontificia Universidad Catolica de Chile ( Site 0285), Santiago, Region M. De Santiago
Hospital Clinico Universidad de Chile ( Site 0287), Santiago, Region M. De Santiago
Beijing Cancer Hospital ( Site 0221), Beijing, Beijing
Zhejiang Cancer Hospital ( Site 0231), Hangzhou, Zhejiang
Sir Run Run Shaw Hospital ( Site 0233), Hangzhou, Zhejiang
SA Pohja-Eesti Regionaalhaigla ( Site 0526), Tallinn, Harjumaa
Hopital Prive Jean Mermoz ( Site 0462), Lyon, Auvergne
Institut Paoli Calmettes ( Site 0472), Marseille, Bouches-du-Rhone
CHU Reims - Hopital Robert Debre ( Site 0465), Reims, Champagne-Ardenne
CHU Brest - Institut de Cancerologie et d Hematologie ( Site 0474), Brest, Finistere
CHU Toulouse - Hopital Rangueil ( Site 0470), Toulouse, Haute-Garonne
Institut du Cancer de Montpellier ( Site 0473), Montpellier, Herault
Centre Eugene Marquis ( Site 0466), Rennes, Ille-et-Vilaine
Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0469), Saint Herblain, Loire-Atlantique
CHRU Lille - Hopital Claude Huriez ( Site 0461), Lille, Nord
CHU Poitiers - Pole Regional de Cancerologie ( Site 0467), Poitiers, Vienne
CHU Hopital Saint Antoine ( Site 0471), Paris, Not set
Institut Mutualiste Montsouris ( Site 0463), Paris, Not set
Klinikum Esslingen GmbH ( Site 0453), Esslingen, Baden-Wurttemberg
Universitaetsklinikum Freiburg ( Site 0450), Freiburg, Baden-Wurttemberg
Klinikum der Universitaet in Muenchen ( Site 0446), Muenchen, Bayern
Medizinische Hochschule Hannover ( Site 0449), Hannover, Niedersachsen
Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 0445), Essen, Nordrhein-Westfalen
Medizinische klinilk und Poliklinik Johannes Gutenberg Univ ( Site 0455), Mainz, Rheinland-Pfalz
Universitaetsklinikum Carl Gustav Carus der TU Dresden ( Site 0448), Dresden, Sachsen
Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 0454), Hamburg, Not set
Integra Cancer Institute ( Site 0262), Guatemala, Not set
Grupo Medico Angeles ( Site 0261), Guatemala, Not set
Centro Medico Integral De Cancerología (CEMIC) ( Site 0260), Quetzaltenango, Not set
Soroka University M.C ( Site 0385), Beer Sheva, HaDarom
Meir medical center ( Site 0386), Kfar Saba, HaMerkaz
Sourasky Medical Center. ( Site 0382), Tel-Aviv, Tell Abib
Rambam Health Care Campus ( Site 0381), Haifa, Not set
Hadassah Medical Center. Ein Kerem ( Site 0383), Jerusalem, Not set
Rabin-Medical Center ( Site 0384), Petah Tikva, Not set
Sheba Medical center ( Site 0387), Ramat Gan, Not set
IRCCS Istituto Oncologico Veneto ( Site 0431), Padova, Abruzzo
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0430), Milano, Lombardia
Istituto Clinico Humanitas Research Hospital ( Site 0432), Rozzano, Milano
IRCCS Policlinico San Donato ( Site 0433), San Donato Milanese, Milano
Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0429), Modena, Not set
Seconda Universita Napoli ( Site 0436), Napoli, Not set
A.O.U. Santa Maria della Misericordia di Udine ( Site 0434), Udine, Not set
Aichi Cancer Center Hospital ( Site 0165), Nagoya, Aichi
National Cancer Center Hospital East ( Site 0178), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 0186), Matsuyama, Ehime
Hokkaido University Hospital ( Site 0160), Sapporo, Hokkaido
Hyogo Cancer Center ( Site 0182), Akashi, Hyogo
Kobe University Hospital ( Site 0188), Kobe, Hyogo
Kobe City Medical Center General Hospital ( Site 0181), Kobe, Hyogo
Ibaraki Prefectural Central Hospital ( Site 0177), Kasama, Ibaraki
Iwate Medical University Hospital ( Site 0184), Shiwa-gun, Iwate
St. Marianna University School of Medicine Hospital ( Site 0187), Kawasaki, Kanagawa
Kanagawa Cancer Center ( Site 0167), Yokohama, Kanagawa
Kansai Medical University Hospital ( Site 0190), Hirakata, Osaka
Osaka University Hospital ( Site 0162), Suita, Osaka
Osaka Medical College Hospital ( Site 0168), Takatsuki, Osaka
Saitama Cancer Center ( Site 0170), Kitaadachi-gun, Saitama
Shizuoka Cancer Center Hospital and Research Institute ( Site 0176), Sunto-gun, Shizuoka
Chiba Cancer Center ( Site 0180), Chiba, Not set
National Hospital Organization Kyushu Cancer Center ( Site 0172), Fukuoka, Not set
Kyushu University Hospital ( Site 0173), Fukuoka, Not set
Gifu University Hospital ( Site 0166), Gifu, Not set
Hiroshima City Hiroshima Citizens Hospital ( Site 0171), Hiroshima, Not set
Kochi Health Sciences Center ( Site 0189), Kochi, Not set
Kumamoto University Hospital ( Site 0164), Kumamoto, Not set
Niigata Cancer Center Hospital ( Site 0169), Niigata, Not set
Osaka International Cancer Institute ( Site 0161), Osaka, Not set
Osaka General Medical Center ( Site 0159), Osaka, Not set
National Cancer Center Hospital ( Site 0179), Tokyo, Not set
Tokyo Metropolitan Komagome Hospital ( Site 0183), Tokyo, Not set
The Cancer Institute Hospital of JFCR ( Site 0185), Tokyo, Not set
Toyama Prefectural Central Hospital ( Site 0163), Toyama, Not set
Chonnam National University Hwasun Hospital ( Site 0083), Hwasun Gun, Jeonranamdo
Seoul National University Bundang Hospital ( Site 0085), Seongnam-si, Kyonggi-do
Kyungpook National University Chilgok Hospital ( Site 0089), Daegu, Taegu-Kwangyokshi
Gachon University Gil Medical Center ( Site 0087), Incheon, Not set
Korea University Anam Hospital ( Site 0084), Seoul, Not set
Seoul National University Hospital -SNUH- ( Site 0080), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 0081), Seoul, Not set
Asan Medical Center ( Site 0082), Seoul, Not set
Gangnam Severance Hospital ( Site 0088), Seoul, Not set
SMG-SNU BORAMAE Medical Center ( Site 0086), Seoul, Not set
Riga East Clinical University Hospital ( Site 0550), Riga, Not set
LSMUL Kauno Klinikos ( Site 0570), Kaunas, Not set
Nacionalinis Vezio Institutas ( Site 0569), Vilnius, Not set
Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 0568), Vilnius, Not set
Hospital Kuala Lumpur ( Site 0146), Kuala Lumpur, Not set
University Malaya Medical Centre ( Site 0143), Kuala Lumpur, Not set
St. Luke s Medical Center ( Site 0622), Quezon City, National Capital Region
Wojewodzki Szpital Specjalistyczny we Wroclawiu ( Site 0358), Wroclaw, Dolnoslaskie
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 0351), Lublin, Lubelskie
Szpital Uniwersytecki w Krakowie ( Site 0352), Krakow, Malopolskie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0349), Warszawa, Mazowieckie
Mazowiecki Szpital Onkologiczny ( Site 0363), Wieliszew, Mazowieckie
Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0353), Koscierzyna, Pomorskie
Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 0354), Bielsko-Biala, Slaskie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0361), Gliwice, Slaskie
SPZOZ WSS nr 3 w Rybniku ( Site 0357), Rybnik, Slaskie
Kaluga Regional Clinical Oncology Center ( Site 0345), Kaluga, Kaluzskaja Oblast
SBHI Leningrad Regional Clinical Hospital ( Site 0496), Saint Petersburg, Leningradskaya Oblast
National Medical and Surgical Center n.a. N.I.Pirogov ( Site 0338), Moscow, Moskva
Blokhin National Medical Oncology ( Site 0494), Moscow, Moskva
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0344), Saint Petersburg, Sankt-Peterburg
Leningrad Regional Oncology Center ( Site 0335), Saint-Petersburg, Sankt-Peterburg
City clinical oncological dispensary ( Site 0336), Sankt-Petersburg, Sankt-Peterburg
Tomsk Scientific Research Institute of Oncology ( Site 0337), Tomsk, Tomskaya Oblast
National University Hospital ( Site 0095), Singapore, Central Singapore
National Cancer Centre Singapore ( Site 0097), Singapore, Central Singapore
Oncocare Cancer Centre ( Site 0096), Singapore, Central Singapore
Taipei Medical University Shuang Ho Hospital ( Site 0068), New Taipei, Not set
National Cheng Kung University Hospital ( Site 0067), Tainan, Not set
National Taiwan University Hospital ( Site 0063), Taipei, Not set
Mackay Memorial Hospital ( Site 0065), Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0066), Taipei, Not set
Chang Gung Medical Foundation. Linkou ( Site 0064), Taoyuan, Not set
City Clinical Hosp.4 of DCC ( Site 0325), Dnipro, Dnipropetrovska Oblast
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 0589), Kryviy Rih, Dnipropetrovska Oblast
Ivano-Frankivsk Regional Oncology Clinical Dispensary ( Site 0321), Ivano-Frankivsk, Ivano-Frankivska Oblast
Communal non profit enterprise Regional Clinical Oncology Center ( Site 0591), Kharkiv, Kharkivska Oblast
National Cancer Institute of the MoH of Ukraine ( Site 0319), Kyiv, Kyivska Oblast
Kyiv City Clinical Oncology Center ( Site 0590), Kyiv, Kyivska Oblast
University Hospitals Bristol NHS Foundation Trust ( Site 0407), Bristol, Bristol, City Of
Ninewells Hospital and Medical School ( Site 0406), Dundee, Dundee City
Royal Free London NHS Foundation Trust ( Site 0403), London, London, City Of
The Royal Marsden Foundation Trust ( Site 0405), London, London, City Of
Imperial College Healthcare NHS Trust ( Site 0402), London, London, City Of
Royal Marsden NHS Foundation Trust ( Site 0400), Sutton, Surrey
The Christie NHS Foundation Trust ( Site 0397), Manchester, Not set
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Active Not Recruiting
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (inclu... Read More
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra). Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/24/2025
Locations: Research Site, Birmingham, Alabama +221 locations
Research Site, Birmingham, Alabama
Research Site, Bakersfield, California
Research Site, Fullerton, California
Research Site, Los Angeles, California
Research Site, Salinas, California
Research Site, Santa Barbara, California
Research Site, Truckee, California
Research Site, New Haven, Connecticut
Research Site, Washington, District of Columbia
Research Site, Orlando, Florida
Research Site, Chicago, Illinois
Research Site, Fort Wayne, Indiana
Research Site, Kansas City, Kansas
Research Site, Louisville, Kentucky
Research Site, New Orleans, Louisiana
Research Site, Grand Rapids, Michigan
Research Site, Bozeman, Montana
Research Site, New Hyde Park, New York
Research Site, New York, New York
Research Site, New York, New York
Research Site, Rochester, New York
Research Site, Germantown, Tennessee
Research Site, Fort Worth, Texas
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Ciudad de Buenos Aires, Not set
Research Site, Ciudad de Buenos Aires, Not set
Research Site, Rosario, Not set
Research Site, Box Hill, Not set
Research Site, Elizabeth Vale, Not set
Research Site, Kogarah, Not set
Research Site, Macquarie University, Not set
Research Site, Murdoch, Not set
Research Site, Orange, Not set
Research Site, South Brisbane, Not set
Research Site, St Albans, Not set
Research Site, Curitiba, Not set
Research Site, Fortaleza, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Ribeirão Preto, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Salvador, Not set
Research Site, Santa Maria, Not set
Research Site, Sao Paulo, Not set
Research Site, São José do Rio Preto, Not set
Research Site, São Paulo, Not set
Research Site, Pleven, Not set
Research Site, Plovdiv, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Calgary, Alberta
Research Site, Edmonton, Alberta
Research Site, Vancouver, British Columbia
Research Site, Hamilton, Ontario
Research Site, Ottawa, Ontario
Research Site, Toronto, Ontario
Research Site, Montreal, Quebec
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chongqing, Not set
Research Site, Chongqing, Not set
Research Site, Dalian, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Jinan, Not set
Research Site, Nanchang, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Suzhou, Not set
Research Site, Tianjin, Not set
Research Site, Tianjin, Not set
Research Site, Urumqi, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Brno, Not set
Research Site, Hradec Kralove, Not set
Research Site, Olomouc, Not set
Research Site, Ostrava, Not set
Research Site, Praha 2, Not set
Research Site, Praha 8, Not set
Research Site, Praha, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Debrecen, Not set
Research Site, Győr, Not set
Research Site, Kecskemét, Not set
Research Site, Szolnok, Not set
Research Site, Gurgaon, Not set
Research Site, Hubli, Not set
Research Site, Kolkata, Not set
Research Site, Mysuru, Not set
Research Site, Nagpur, Not set
Research Site, Nasik, Not set
Research Site, New Delhi, Not set
Research Site, New Delhi, Not set
Research Site, Pune, Not set
Research Site, Haifa, Not set
Research Site, Jerusalem, Not set
Research Site, Kfar Saba, Not set
Research Site, Petach-Tikva, Not set
Research Site, Ramat Gan, Not set
Research Site, Arezzo, Not set
Research Site, Milano, Not set
Research Site, Milano, Not set
Research Site, Napoli, Not set
Research Site, Orbassano, Not set
Research Site, Parma, Not set
Research Site, Pavia, Not set
Research Site, Roma, Not set
Research Site, Terni, Not set
Research Site, Verona, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Hirosaki-shi, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kita-gun, Not set
Research Site, Koshigaya-shi, Not set
Research Site, Koto-ku, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Kyoto-shi, Not set
Research Site, Miyazaki-city, Not set
Research Site, Nagasaki-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Niigata-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Shinjuku-ku, Not set
Research Site, Suita-shi, Not set
Research Site, Toyama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Goyang-si, Not set
Research Site, Incheon, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon, Not set
Research Site, Bacolod, Not set
Research Site, Baguio City, Not set
Research Site, Cebu, Not set
Research Site, Davao City, Not set
Research Site, Makati, Not set
Research Site, Manila, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, Bialystok, Not set
Research Site, Gdańsk, Not set
Research Site, Grudziądz, Not set
Research Site, Koszalin, Not set
Research Site, Kraków, Not set
Research Site, Olsztyn, Not set
Research Site, Poznan, Not set
Research Site, Radom, Not set
Research Site, Warszawa, Not set
Research Site, Ivanovo, Not set
Research Site, Krasnoyarsk, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Nizhniy Novgorod, Not set
Research Site, Nizhniy Novgorod, Not set
Research Site, Omsk, Not set
Research Site, Rostov-on-Don, Not set
Research Site, Saint-Petersburg, Not set
Research Site, St. Petersburg, Not set
Research Site, St. Petersburg, Not set
Research Site, Tyumen, Not set
Research Site, Vologda, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Lugo, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Malaga, Not set
Research Site, Santander, Not set
Research Site, Sevilla, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Tainan, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Khon Kaen, Not set
Research Site, Mueang, Not set
Research Site, Songkla, Not set
Research Site, Adana, Not set
Research Site, Adapazari, Not set
Research Site, Ankara, Not set
Research Site, Edirne, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Ha Noi, Not set
Research Site, Hanoi, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh, Not set
Conditions: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
Active Not Recruiting
You are being asked to take part in this study because you have a biliary cancer that is incurable and has spread to other organs. Chemotherapy is often used to help shrink the cancer temporarily and may improve survival. In Canada, the combination of gemcitabine and cisplatin is the chemotherapy combination used to treat biliary cancer that has spread. There is no other known treatment for biliary cancer that has spread to other organs. It is hoped that this new combination of drugs (nab-paclit... Read More
You are being asked to take part in this study because you have a biliary cancer that is incurable and has spread to other organs. Chemotherapy is often used to help shrink the cancer temporarily and may improve survival. In Canada, the combination of gemcitabine and cisplatin is the chemotherapy combination used to treat biliary cancer that has spread. There is no other known treatment for biliary cancer that has spread to other organs. It is hoped that this new combination of drugs (nab-paclitaxel, gemcitabine, and cisplatin) will improve the tumor shrinkage rate.
This study is being done because we do not know whether 2 or 3 chemotherapy drugs is better to treat biliary cancers.
We hope to learn whether giving nab-paclitaxel, gemcitabine, and cisplatin together in patients with biliary cancer can increase tumor shrinkage without too many side effects.
The purpose of this study is to find out what effects (good and bad) nab-paclitaxel, gemcitabine, and cisplatin has on you and your biliary cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Cross Cancer Institute, Edmonton, Alberta +1 locations
Cross Cancer Institute, Edmonton, Alberta
Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Unresectable Biliary Tract Cancer
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Recruiting
A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol
1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
2. HCC Durvalumab will be administered once every 4 weeks in combination with continuous propranolol... Read More
A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol
1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
2. HCC Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
3. Biliary Tract Cancer (BTC, Cholangiocarcinoma of the gallbladder or bile ducts) Durvalumab will be administered once every 3 weeks, in combination with cisplatin + gemcitabine (day 1/8) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Cross Cancer Institute, Edmonton, Alberta
Cross Cancer Institute, Edmonton, Alberta
49 - 60 of 326